Tonlamarsen vs Zilebesiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertension

Shared mechanism: Angiotensinogen (AGT) · full Hypertension pipeline

Tonlamarsen

Developed by Kardigan under a licence from Ionis Pharmaceuticals

Phase 2 in Hypertensionantisense oligonucleotide
Partial signal

NCT06864104 · Phase 2 · completed

The study randomized 198 participants (206 entered the active run-in) to monthly tonlamarsen or to a single tonlamarsen dose followed by placebo, with participants, care providers, investigators and outcome assessors masked. It had two co-primary outcomes at week 20. Plasma angiotensinogen fell more with monthly dosing (P<0.0001), but office systolic blood pressure fell by 6.7 mm Hg in both groups (P=0.97). One co-primary outcome was met and one was missed, so the result is mixed. The figures are from the peer-reviewed publication (JACC 2026) and the registry's primary outcome list.

Next expected readout: December 2026 · NCT07511361 (registry estimate)

Reported efficacy

Co-primary: change from baseline to week 20 in plasma angiotensinogen and in office systolic blood pressure (between-group differences): Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed. (mixed)

Result source: NCT06864104

Zilebesiran

Developed by Alnylam Pharmaceuticals and partners

Phase 3 in HypertensionRNAi (siRNA)
Reliable signal

NCT04936035 · Phase 2 · completed

The study randomized 394 participants to placebo or zilebesiran and maintained quadruple blinding, with approximately 60–75 participants per treatment group analyzed for the primary endpoint. The primary clinical endpoint—change in 24-hour ambulatory systolic blood pressure at Month 3—was significantly favorable for zilebesiran versus placebo, supporting strong evidence from this trial.

Next expected readout: September 2030 · NCT07181109 (registry estimate)

Reported efficacy

Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3): Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3): Placebo 6.8 millimeters of mercury (mmHg) ± 1.58 vs Zilebesiran 150 mg Q6M -7.3 millimeters of mercury (mmHg) ± 1.49 vs Zilebesiran 300 mg Q6M and Q3M -10.0 millimeters of mercury (mmHg) ± 1.05 vs Zilebesiran 600 mg Q6M -8.9 millimeters of mercury (mmHg) ± 1.52; p=<0.0001 (Placebo vs Zilebesiran 300 mg Q6M and Q3M), p=<0.0001 (Placebo vs Zilebesiran 600 mg Q6M) (met)

Result source: NCT04936035

Results for Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTonlamarsenZilebesiran
Seated SBP, change—Not reported-11.1 vs -0.6−10.5 vs placebo300 mg Q6M · wk 24 · n 68NCT04936035
5 other results
  • -12.8 vs -0.6 300 mg Q3M · wk 24 · n 57 · Phase 2 · secondary NCT04936035
  • -10.8 vs -0.6 600 mg Q6M · wk 24 · n 62 · Phase 2 · secondary NCT04936035
  • -9.2 vs -0.1 600 mg Q6M · wk 12 · n 64 · Phase 2 · secondary NCT04936035
  • -8.2 vs -0.6 150 mg Q6M · wk 24 · n 65 · Phase 2 · secondary NCT04936035
  • -9.7 vs -0.1 150 mg Q6M · wk 12 · n 68 · Phase 2 · secondary NCT04936035
24-hour ambulatory SBP, change—Not reported-8.9 vs 6.8−15.7 vs placebo600 mg Q6M · wk 12 · n 65NCT04936035
11 other results
  • -7.3 vs 6.8 150 mg Q6M · wk 12 · n 68 · Phase 2 · primary NCT04936035
  • -15.7 vs -3.7 wk 12 · n 53 · Phase 2 · primary NCT05103332
  • -10.5 vs -0.7 wk 12 · n 99 · Phase 2 · primary NCT05103332
  • -7.7 vs -3.2 wk 12 · n 115 · Phase 2 · primary NCT05103332
  • -9.9 vs 4.6 300 mg Q6M · wk 24 · n 68 · Phase 2 · secondary NCT04936035
  • -9.5 vs 4.6 300 mg Q3M · wk 24 · n 60 · Phase 2 · secondary NCT04936035
  • -9.6 vs 4.6 600 mg Q6M · wk 24 · n 63 · Phase 2 · secondary NCT04936035
  • -6.5 vs 4.6 150 mg Q6M · wk 24 · n 62 · Phase 2 · secondary NCT04936035
  • -15.6 vs -4.6 wk 24 · n 53 · Phase 2 · secondary NCT05103332
  • -9.7 vs -1.8 wk 24 · n 103 · Phase 2 · secondary NCT05103332
  • -7.6 vs -5.8 wk 24 · n 116 · Phase 2 · secondary NCT05103332
Seated DBP, change—Not reported-6.8 vs -1.2−5.6 vs placebo300 mg Q6M · wk 24 · n 68NCT04936035
5 other results
  • -8.2 vs -1.2 300 mg Q3M · wk 24 · n 57 · Phase 2 · secondary NCT04936035
  • -5 vs -1.2 600 mg Q6M · wk 24 · n 62 · Phase 2 · secondary NCT04936035
  • -5.4 vs -0.6 600 mg Q6M · wk 12 · n 64 · Phase 2 · secondary NCT04936035
  • -4.1 vs -1.2 150 mg Q6M · wk 24 · n 65 · Phase 2 · secondary NCT04936035
  • -5.3 vs -0.6 150 mg Q6M · wk 12 · n 68 · Phase 2 · secondary NCT04936035

Seated SBP, change

Tonlamarsen
—Not reported
Zilebesiran
-11.1 vs -0.6−10.5 vs placebo300 mg Q6M · wk 24 · n 68NCT04936035
5 other results
  • -12.8 vs -0.6 300 mg Q3M · wk 24 · n 57 · Phase 2 · secondary NCT04936035
  • -10.8 vs -0.6 600 mg Q6M · wk 24 · n 62 · Phase 2 · secondary NCT04936035
  • -9.2 vs -0.1 600 mg Q6M · wk 12 · n 64 · Phase 2 · secondary NCT04936035
  • -8.2 vs -0.6 150 mg Q6M · wk 24 · n 65 · Phase 2 · secondary NCT04936035
  • -9.7 vs -0.1 150 mg Q6M · wk 12 · n 68 · Phase 2 · secondary NCT04936035

24-hour ambulatory SBP, change

Tonlamarsen
—Not reported
Zilebesiran
-8.9 vs 6.8−15.7 vs placebo600 mg Q6M · wk 12 · n 65NCT04936035
11 other results
  • -7.3 vs 6.8 150 mg Q6M · wk 12 · n 68 · Phase 2 · primary NCT04936035
  • -15.7 vs -3.7 wk 12 · n 53 · Phase 2 · primary NCT05103332
  • -10.5 vs -0.7 wk 12 · n 99 · Phase 2 · primary NCT05103332
  • -7.7 vs -3.2 wk 12 · n 115 · Phase 2 · primary NCT05103332
  • -9.9 vs 4.6 300 mg Q6M · wk 24 · n 68 · Phase 2 · secondary NCT04936035
  • -9.5 vs 4.6 300 mg Q3M · wk 24 · n 60 · Phase 2 · secondary NCT04936035
  • -9.6 vs 4.6 600 mg Q6M · wk 24 · n 63 · Phase 2 · secondary NCT04936035
  • -6.5 vs 4.6 150 mg Q6M · wk 24 · n 62 · Phase 2 · secondary NCT04936035
  • -15.6 vs -4.6 wk 24 · n 53 · Phase 2 · secondary NCT05103332
  • -9.7 vs -1.8 wk 24 · n 103 · Phase 2 · secondary NCT05103332
  • -7.6 vs -5.8 wk 24 · n 116 · Phase 2 · secondary NCT05103332

Seated DBP, change

Tonlamarsen
—Not reported
Zilebesiran
-6.8 vs -1.2−5.6 vs placebo300 mg Q6M · wk 24 · n 68NCT04936035
5 other results
  • -8.2 vs -1.2 300 mg Q3M · wk 24 · n 57 · Phase 2 · secondary NCT04936035
  • -5 vs -1.2 600 mg Q6M · wk 24 · n 62 · Phase 2 · secondary NCT04936035
  • -5.4 vs -0.6 600 mg Q6M · wk 12 · n 64 · Phase 2 · secondary NCT04936035
  • -4.1 vs -1.2 150 mg Q6M · wk 24 · n 65 · Phase 2 · secondary NCT04936035
  • -5.3 vs -0.6 150 mg Q6M · wk 12 · n 68 · Phase 2 · secondary NCT04936035
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Tonlamarsen
Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed. NCT06864104 · Phase 2 · design grade: moderate · publication or press release
(-6% v. -79%, PBO v. 90 mg, p=0.001); median AGT reductions (-5% v. -86%, PBO v. 90 mg) NCT05314439 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Tonlamarsen: 0 of 4 rows · Zilebesiran: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricZilebesiran
Dropout rate
6.7%300 mg Q3Ma
NCT04936035 · Phase 2
show 18 more results
4.1%300 mg Q6M
NCT04936035 · Phase 2
—300 mg Q3M
NCT04936035 · Phase 2
—300 mg Q6M
NCT04936035 · Phase 2
6.6%600 mg Q6M
NCT04936035 · Phase 2
—600 mg Q6M
NCT04936035 · Phase 2
—150 mg Q6M
NCT04936035 · Phase 2
—150 mg Q6M
NCT04936035 · Phase 2
—DB (Zilebesiran) to SFU or OLE to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB (Zilebesiran) to SFU or OLE to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB (Zilebesiran) to SFU or OLE to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB Period (Zilebesiran) to OLE Per
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB Period (Zilebesiran) to OLE Per
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB Period (Zilebesiran) to OLE Per
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
4.2%DB Period: Zilebesiran (Add-on to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
9.2%DB Period: Zilebesiran (Add-on to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
5.4%DB Period: Zilebesiran (Add-on to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
8.3%300 mg
NCT06423352 · Phase 1/2 · registry result, not featured evidence
8.3%600 mg
NCT06423352 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
0%300 mg Q3Ma
NCT04936035 · Phase 2
show 18 more results
0%300 mg Q6M
NCT04936035 · Phase 2
—300 mg Q3M
NCT04936035 · Phase 2
—300 mg Q6M
NCT04936035 · Phase 2
0%600 mg Q6M
NCT04936035 · Phase 2
—600 mg Q6M
NCT04936035 · Phase 2
—150 mg Q6M
NCT04936035 · Phase 2
—150 mg Q6M
NCT04936035 · Phase 2
—DB (Zilebesiran) to SFU or OLE to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB (Zilebesiran) to SFU or OLE to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB (Zilebesiran) to SFU or OLE to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB Period (Zilebesiran) to OLE Per
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB Period (Zilebesiran) to OLE Per
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB Period (Zilebesiran) to OLE Per
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB Period: Zilebesiran (Add-on to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB Period: Zilebesiran (Add-on to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—DB Period: Zilebesiran (Add-on to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
—300 mg
NCT06423352 · Phase 1/2 · registry result, not featured evidence
—600 mg
NCT06423352 · Phase 1/2 · registry result, not featured evidence
Serious AEs
5.3%300 mg Q3Ma
NCT04936035 · Phase 2
show 18 more results
1.4%300 mg Q6M
NCT04936035 · Phase 2
9.3%300 mg Q3M
NCT04936035 · Phase 2
6.8%300 mg Q6M
NCT04936035 · Phase 2
7.9%600 mg Q6M
NCT04936035 · Phase 2
11.8%600 mg Q6M
NCT04936035 · Phase 2
0%150 mg Q6M
NCT04936035 · Phase 2
6.4%150 mg Q6M
NCT04936035 · Phase 2
0%DB (Zilebesiran) to SFU or OLE to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
1.1%DB (Zilebesiran) to SFU or OLE to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
0.5%DB (Zilebesiran) to SFU or OLE to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
2.5%DB Period (Zilebesiran) to OLE Per
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
1.6%DB Period (Zilebesiran) to OLE Per
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
4.7%DB Period (Zilebesiran) to OLE Per
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
2.5%DB Period: Zilebesiran (Add-on to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
0%DB Period: Zilebesiran (Add-on to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
2.7%DB Period: Zilebesiran (Add-on to
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
0%300 mg
NCT06423352 · Phase 1/2 · registry result, not featured evidence
0%600 mg
NCT06423352 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
300 mg Q3Ma
injection site reaction 10.7% (placebo 0%)
coronavirus disease of 2019 (covid-19) 8% (placebo 4%)
hyperkalaemia 6.7% (placebo 1.3%)
NCT04936035 · Phase 2
show 18 more results
300 mg Q6M
coronavirus disease of 2019 (covid-19) 8.2% (placebo 4%)
arthralgia 5.5% (placebo 2.7%)
headache 5.5% (placebo 9.3%)
NCT04936035 · Phase 2
300 mg Q3M
injection site reaction 17.3% (placebo 0%)
coronavirus disease of 2019 (covid-19) 12% (placebo 4%)
urinary tract infection 12% (placebo 0%)
NCT04936035 · Phase 2
300 mg Q6M
injection site reaction 11% (placebo 0%)
coronavirus disease of 2019 (covid-19) 9.6% (placebo 4%)
arthralgia 8.2% (placebo 2.7%)
NCT04936035 · Phase 2
600 mg Q6M
hyperkalaemia 6.6% (placebo 1.3%)
hypertension 6.6% (placebo 6.7%)
coronavirus disease of 2019 (covid-19) 5.3% (placebo 4%)
NCT04936035 · Phase 2
600 mg Q6M
hypertension 11.8% (placebo 6.7%)
injection site reaction 11.8% (placebo 0%)
coronavirus disease of 2019 (covid-19) 10.5% (placebo 4%)
NCT04936035 · Phase 2
150 mg Q6M
hyperkalaemia 6.4% (placebo 1.3%)
hypertension 5.1% (placebo 6.7%)
coronavirus disease of 2019 (covid-19) 3.8% (placebo 4%)
NCT04936035 · Phase 2
150 mg Q6M
hypertension 11.5% (placebo 6.7%)
coronavirus disease of 2019 (covid-19) 9% (placebo 4%)
hyperkalaemia 7.7% (placebo 1.3%)
NCT04936035 · Phase 2
covid-19 0% (placebo 0%)
dizziness 0% (placebo 0%)
headache 0% (placebo 0%)
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
covid-19 0% (placebo 0%)
dizziness 0% (placebo 0%)
headache 0% (placebo 0%)
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
covid-19 0% (placebo 0%)
dizziness 0% (placebo 0%)
headache 0% (placebo 0%)
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
covid-19 7.6% (placebo 0%)
dizziness 6.8% (placebo 0%)
hypertension 6.8% (placebo 0%)
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
hypertension 11.1% (placebo 0%)
headache 9.5% (placebo 0%)
injection site reaction 7.9% (placebo 0%)
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
hypertension 9.5% (placebo 0%)
dizziness 8.1% (placebo 0%)
hyperkalaemia 6.8% (placebo 0%)
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
covid-19 5.1% (placebo 0%)
dizziness 5.1% (placebo 0%)
hypertension 5.1% (placebo 0%)
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
headache 6.3% (placebo 0%)
hypertension 6.3% (placebo 0%)
injection site reaction 6.3% (placebo 0%)
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
hypertension 9.5% (placebo 0%)
dizziness 7.4% (placebo 0%)
hyperkalaemia 5.4% (placebo 0%)
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
300 mg
headache 16.7% (placebo 0%)
pharyngitis 16.7% (placebo 0%)
alanine aminotrasferase increased 8.3% (placebo 0%)
NCT06423352 · Phase 1/2 · registry result, not featured evidence
600 mg
influenza 16.7% (placebo 0%)
blood alkaline phosphatase increased 8.3% (placebo 0%)
blood potassium increased 8.3% (placebo 0%)
NCT06423352 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Zilebesiran

Ambulatory SBP -9.9 vs 4.6 placebo mmHg @ 24wk300 mg Q6M
absolute change · mmHg
NCT04936035 · Phase 2
show 11 more results
-9.5 vs 4.6 placebo mmHg @ 24wk300 mg Q3M
NCT04936035 · Phase 2
-8.9 vs 6.8 placebo mmHg @ 12wk600 mg Q6M
NCT04936035 · Phase 2
-9.6 vs 4.6 placebo mmHg @ 24wk600 mg Q6M
NCT04936035 · Phase 2
-7.3 vs 6.8 placebo mmHg @ 12wk150 mg Q6M
NCT04936035 · Phase 2
-6.5 vs 4.6 placebo mmHg @ 24wk150 mg Q6M
NCT04936035 · Phase 2
-15.7 vs -3.7 placebo mmHg @ 12wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-10.5 vs -0.7 placebo mmHg @ 12wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-7.7 vs -3.2 placebo mmHg @ 12wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-15.6 vs -4.6 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-9.7 vs -1.8 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-7.6 vs -5.8 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
Seated SBP -11.1 vs -0.6 placebo mmHg @ 24wk300 mg Q6M
absolute change · mmHg
NCT04936035 · Phase 2
show 5 more results
-12.8 vs -0.6 placebo mmHg @ 24wk300 mg Q3M
NCT04936035 · Phase 2
-9.2 vs -0.1 placebo mmHg @ 12wk600 mg Q6M
NCT04936035 · Phase 2
-10.8 vs -0.6 placebo mmHg @ 24wk600 mg Q6M
NCT04936035 · Phase 2
-9.7 vs -0.1 placebo mmHg @ 12wk150 mg Q6M
NCT04936035 · Phase 2
-8.2 vs -0.6 placebo mmHg @ 24wk150 mg Q6M
NCT04936035 · Phase 2
Ambulatory SBP Control 50.7% (n=73) vs 6.7% (n=75) placebo @ 24wk300 mg Q6M
responder rate · % of participants
NCT04936035 · Phase 2
show 6 more results
38.7% (n=75) vs 6.7% (n=75) placebo @ 24wk300 mg Q3M
NCT04936035 · Phase 2
47.4% (n=76) vs 6.7% (n=75) placebo @ 24wk600 mg Q6M
NCT04936035 · Phase 2
30.8% (n=78) vs 6.7% (n=75) placebo @ 24wk150 mg Q6M
NCT04936035 · Phase 2
64.2% (n=53) vs 14% (n=57) placebo @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
39.8% (n=103) vs 13.7% (n=102) placebo @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
25.9% (n=116) vs 17.2% (n=128) placebo @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
Ambulatory DBP -6.1 vs 2.2 placebo mmHg @ 24wk300 mg Q6M
absolute change · mmHg
NCT04936035 · Phase 2
show 11 more results
-6.3 vs 2.2 placebo mmHg @ 24wk300 mg Q3M
NCT04936035 · Phase 2
-5.8 vs 3.5 placebo mmHg @ 12wk600 mg Q6M
NCT04936035 · Phase 2
-6.3 vs 2.2 placebo mmHg @ 24wk600 mg Q6M
NCT04936035 · Phase 2
-4.5 vs 3.5 placebo mmHg @ 12wk150 mg Q6M
NCT04936035 · Phase 2
-4.8 vs 2.2 placebo mmHg @ 24wk150 mg Q6M
NCT04936035 · Phase 2
-9.1 vs -1.3 placebo mmHg @ 12wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-8.5 vs -2.3 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-6.6 vs -0.8 placebo mmHg @ 12wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-6.2 vs -1.1 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-3.4 vs -1.4 placebo mmHg @ 12wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-3.5 vs -3.1 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
Seated DBP -6.8 vs -1.2 placebo mmHg @ 24wk300 mg Q6M
absolute change · mmHg
NCT04936035 · Phase 2
show 5 more results
-8.2 vs -1.2 placebo mmHg @ 24wk300 mg Q3M
NCT04936035 · Phase 2
-5.4 vs -0.6 placebo mmHg @ 12wk600 mg Q6M
NCT04936035 · Phase 2
-5 vs -1.2 placebo mmHg @ 24wk600 mg Q6M
NCT04936035 · Phase 2
-5.3 vs -0.6 placebo mmHg @ 12wk150 mg Q6M
NCT04936035 · Phase 2
-4.1 vs -1.2 placebo mmHg @ 24wk150 mg Q6M
NCT04936035 · Phase 2
SBP -19.3 vs -0.8 placebo mmHg @ 12wk
absolute change · mmHg
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
show 5 more results
-18.1 vs -4.5 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-11.5 vs -1.4 placebo mmHg @ 12wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-11.5 vs -2.9 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-9.3 vs -2.6 placebo mmHg @ 12wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-10.8 vs -6.3 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
DBP -10.5 vs -0.2 placebo mmHg @ 12wk
absolute change · mmHg
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
show 5 more results
-9.5 vs -2 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-6.2 vs -1.2 placebo mmHg @ 12wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-6.2 vs -1.4 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-5.3 vs -2 placebo mmHg @ 12wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
-5.8 vs -3.5 placebo mmHg @ 24wk
NCT05103332 · Phase 2 · registry result, not featured evidence · combination
Ambulatory SBP -15.2 vs 0.4 placebo mmHg @ 13wk300 mg
absolute change · mmHg
Month 3 SBP (Change from Baseline)
NCT06423352 · Phase 1/2 · registry result, not featured evidence
show 1 more result
-17.8 vs 0.4 placebo mmHg @ 13wk600 mg
Month 3 SBP (Change from Baseline)
NCT06423352 · Phase 1/2 · registry result, not featured evidence
Ambulatory SBP -12.6 vs -6.5 placebo mmHg @ 26wk300 mg
absolute change · mmHg
Month 6 SBP (Change from Baseline)
NCT06423352 · Phase 1/2 · registry result, not featured evidence
show 1 more result
-12.2 vs -6.5 placebo mmHg @ 26wk600 mg
Month 6 SBP (Change from Baseline)
NCT06423352 · Phase 1/2 · registry result, not featured evidence
Ambulatory DBP -8.6 vs 0.3 placebo mmHg @ 13wk300 mg
absolute change · mmHg
Month 3 DBP (Change from Baseline)
NCT06423352 · Phase 1/2 · registry result, not featured evidence
show 1 more result
-9.2 vs 0.3 placebo mmHg @ 13wk600 mg
Month 3 DBP (Change from Baseline)
NCT06423352 · Phase 1/2 · registry result, not featured evidence
Ambulatory DBP -7.1 vs -3.9 placebo mmHg @ 26wk300 mg
absolute change · mmHg
Month 6 DBP (Change from Baseline)
NCT06423352 · Phase 1/2 · registry result, not featured evidence
show 1 more result
-8.2 vs -3.9 placebo mmHg @ 26wk600 mg
Month 6 DBP (Change from Baseline)
NCT06423352 · Phase 1/2 · registry result, not featured evidence
SBP -14.4 vs 4.4 placebo mmHg @ 13wk300 mg
absolute change · mmHg
Month 3 SBP (Change from Baseline)
NCT06423352 · Phase 1/2 · registry result, not featured evidence
show 1 more result
-14.4 vs 4.4 placebo mmHg @ 13wk600 mg
Month 3 SBP (Change from Baseline)
NCT06423352 · Phase 1/2 · registry result, not featured evidence

+ 3 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tonlamarsen's landscape · Zilebesiran's landscape